T-TAS® wS Method Comparison

Ostensibly Healthy Donors Inclusion Criteria: * Males and females age 21 years or older. * Able and willing to provide written informed consent. Exclusion Criteria: * Hospitalization or doctor's visits within prior 30 days, except for routine checkup/physical examination. * Use of antiplatelet therapy within the past 7 days, e.g. aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol. * Use of anticoagulant drugs within the past 7 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban. * Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit COX-1 such as naproxen or ibuprofen within the past 3 days, unless confirmed to not inhibit platelet activity (such as celecoxib). * History of anemia. * Known thrombocytopenia (platelet count \< 100,000/μL). * Significant renal dysfunction or dialysis. * History of platelet disorders e.g. von Willebrand factor deficiency, Glanzmann's thrombasthenia or Bernard-Soulier syndrome. * History of hemophilia or bleeding disorders. * Known active gastrointestinal disease including peptic ulcers, gastro-esophageal reflux disease (GERD), and hyperacidity. * Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis. * Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals. Antiplatelet Therapy Subjects Inclusion Criteria: * Males and females age 21 years or older. * One of the following antiplatelet therapy regimens: * Aspirin monotherapy: * 81 mg or higher aspirin daily for 1 or more days * Dual antiplatelet therapy: * 81 mg or higher aspirin plus either 1) ≥300 mg clopidogrel loading dose within the prior 5 days followed by 75 mg daily clopidogrel, or 2) 75 mg daily clopidogrel daily for ≥5 days. * 81 mg or higher aspirin plus either 1) 60 mg prasugrel loading dose within the prior 5 days followed by either 5 or 10 mg daily prasugrel, or 2) 5 or 10 mg daily prasugrel daily for ≥5 days. * 81 mg aspirin plus either 1) 180 mg ticagrelor loading dose within the prior 5 days followed by 2x90 mg daily ticagrelor, or 2) 2x90 mg daily ticagrelor daily for ≥5 days. * Able and willing to provide written informed consent. Exclusion Criteria: * Use of antiplatelet therapy other than aspirin, clopidogrel, prasugrel, or ticagrelor (e.g. cilostazol, abciximab, eptifibatide) within the past 7 days. * Use of anticoagulant drugs within the past 7 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban. * Significant renal dysfunction or dialysis. * Known thrombocytopenia (platelet count \< 100,000/μL). * History of platelet disorders e.g. von Willebrand factor deficiency, Glanzmann thrombasthenia or Bernard-Soulier syndrome. * History of hemophilia or bleeding disorders. * Females who are in the last trimester of pregnancy or are breastfeeding. * Known active gastrointestinal disease including peptic ulcers, gastro-esophageal reflux disease (GERD), and hyperacidity. * Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis. * Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals. Von Willebrand Disease Subjects Inclusion Criteria: * Males and females age 21 years or older. * Prior diagnosis of von Willebrand disease type 1, 2A, 2B, 2M, or 3 * Able and willing to provide written informed consent. Exclusion Criteria: * Prior diagnosis of von Willebrand disease type 2N * Use of antiplatelet therapy besides aspirin within the past 14 days. * Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban. * Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit COX-1 such as naproxen or ibuprofen within the past 7 days, unless confirmed to not inhibit platelet activity (such as celecoxib). * Significant renal dysfunction or dialysis. * Known thrombocytopenia (platelet count \< 100,000/μL). * Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis. * Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals.